AXNX News and Press, Axonics Modulation Technologies Inc. From 02/16/21

Axonics Modulation Technologies (AXNX) receives PMA supplement approval from the FDA for its third-generation implantable neurostimulator ((INS)). The third-generation INS upgrades the embedded software in the INS and the functionality of the patient remote control. Shipment of the third-gene...

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will participate in the virtual SVB Leerink Global Heal...

For Q4, Axonics Modulation Technologies (AXNX) expects net revenue to be in the range of $34.7-$34.9M vs. $9.9M reported in the year ago quarter.U.S. customers sales represented ~97% of total revenue.In Q4, ~320 confirmed and scheduled permanent implants were canceled due to COVID-19 bas...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenue for th...

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical tech...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtua...

Patients experienced significant clinical benefits and satisfaction with recharging and therapy Clinical outcomes consistent with dual incontinence patients from ARSTISAN pivotal study Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology...

Axonics Modulation Technologies, Inc. (AXNX) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President and Chief Financial Officer Conference Call Participants David Lewi...

Axonics Modulation Technologies, Inc. (AXNX) Q3 2020 Earnings Conference Call October 4, 2020 4:20 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants David Lew...